01-Jul-2019 | Zion Market Research
Zion Market Research has published a new report titled “Psoriatic Arthritis Therapeutics Market by Drug Class (Interleukin Inhibitors, TNF Inhibitors, PDE4 Inhibitors, and Others), by Disease Type (Asymmetric Psoriatic Arthritis, Symmetric Psoriatic Arthritis, Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis, Spondylitis, and Arthritis Mutilans), and by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global psoriatic arthritis therapeutics market was approximately USD 8 billion in 2018 and is expected to generate around USD 16.71 billion by 2025, at a CAGR of around 11.2% between 2019 and 2025.
Psoriatic arthritis is a condition prevalent in psoriasis patients and involves inflammatory arthropathy. This leads to swelling, stiffness, and tenderness of joints caused by the degeneration of cartilage bones in the joints. Sometimes, lesions may appear later than joints problems. This is a non-curable condition, but controlling the symptoms can prevent joint damage. Psoriatic arthritis is caused by abnormal immune responses, which leads to joint inflammation and overproduction of skin cells. Psoriatic arthritis can affect any body part and cause swollen and painful joints that feel warm when touched. The global psoriatic arthritis therapeutics market is mainly driven by the increased prevalence of psoriasis that is leading to the rise in the number of psoriatic arthritis patients. As per the National Psoriasis Foundation report, in 2018, around 10 to 30% percent of people with psoriasis developed psoriatic arthritis. Furthermore, increasing use of biologics, growing R&D activities of pipeline drugs, rising disease awareness among people coupled with a large population with unmet needs is also expected to propel the global psoriatic arthritis therapeutics market. However, stringent regulatory approval process, high cost of drugs, and lack of proper diagnosis of psoriatic arthritis may hamper the psoriatic arthritis therapeutics market globally over the projected time period.
Browse the full “Psoriatic Arthritis Therapeutics Market by Drug Class (Interleukin Inhibitors, TNF Inhibitors, PDE4 Inhibitors, and Others), by Disease Type (Asymmetric Psoriatic Arthritis, Symmetric Psoriatic Arthritis, Distal Interphalangeal Predominant (DIP) Psoriatic Arthritis, Spondylitis, and Arthritis Mutilans), and by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/psoriatic-arthritis-therapeutics-market
The psoriatic arthritis therapeutics market is classified on the basis of drug class, disease type, and distribution channel. By drug class, the market is fragmented into interleukin inhibitors, TNF inhibitors, PDE4 inhibitors, and others. TNF inhibitors are expected to dominate the global psoriatic arthritis therapeutics market in the future. By disease type, the market is categorized into asymmetric psoriatic arthritis, spondylitis, distal interphalangeal predominant (DIP) psoriatic arthritis, symmetric psoriatic arthritis, and arthritis mutilans. The distribution channel includes hospital pharmacies, online pharmacies, and retail pharmacies. Hospital pharmacies are expected to account for the largest market share and grow significantly over the estimated timeframe.
North America is expected to dominate the psoriatic arthritis therapeutics market globally over the forecast time period, owing to the increasing adoption of biologic drugs for arthritis treatment and rising prevalence of psoriatic arthritis. The Asia Pacific psoriatic arthritis therapeutics market is expected to grow notably in the future, due to the presence of developing economies of India and China and increasing healthcare facilities across the region.
Some major players of the psoriatic arthritis therapeutics market include Bristol-Myers Squibb, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company, and AbbVie.
This report segments the global psoriatic arthritis therapeutics market into:
Global Psoriatic Arthritis Therapeutics Market: Drug Class Analysis
Global Psoriatic Arthritis Therapeutics Market: Disease Type Analysis
Global Psoriatic Arthritis Therapeutics Market: Distribution Channel Analysis
Global Psoriatic Arthritis Therapeutics Market: Regional Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651